Sensitivity Comparison between Rapid Immuno-Chromatographic Device Test and ELISA in Detection and Sero-Prevalence of HBsAg and Anti-HCV antibodies in Apparently Healthy Blood Donors of Lahore, Pakistan

Authors: Natasha Hussain, Maleeha Aslam, Robina Farooq

Abstract:

Hepatitis B and hepatitis C are among the most significant hepatic infections all around the world that may lead to hepatocellular carcinoma. This study is first time performed at the blood transfussion centre of Omar hospital, Lahore. It aims to determine the sero-prevalence of these diseases by screening the apparently healthy blood donors who might be the carriers of HBV or HCV and pose a high risk in the transmission. It also aims the comparison between the sensitivity of two diagnostic tests; chromatographic immunoassay – one step test device and Enzyme Linked Immuno Sorbant Assay (ELISA). Blood serum of 855 apparently healthy blood donors was screened for Hepatitis B surface antigen (HBsAg) and for anti HCV antibodies. SPSS version 12.0 and X2 (Chi-square) test were used for statistical analysis. The seroprevalence of HCV was 8.07% by the device method and by ELISA 9.12% and that of HBV was 5.6% by the device and 6.43% by ELISA. The unavailability of vaccination against HCV makes it more prevalent. Comparing the two diagnostic methods, ELISA proved to be more sensitive.

Keywords: ELISA, Sensitivity comparison of diagnostic tests, seroprevalence of Hepatitis B and C

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1086161

References:

[1] Ishtiaque Ahmad C , Samiulah S . Sero prevalence of hepatitis B and C among the healthy blood donors at Fauji Foundation Hospital , Rawal pindi . Pak J Med Sci 2007, pp. 64-67.
[2] Sood S and Malvnker S. Sero prevalence of Hepatitis B surface antigen, anti bodies to the hepatitis C virus , and human immune deficiency virus in a hospital - based population in Jai pur : Rajastan; Indian J. Community Medi. 2010 , pp. 165-169.
[3] Shahin Merat and Houri Rezvan.; The Prevalence of hepatitis B surface antigen and Ani hepatitis B core antibody in Iran; A population based study . Arch Iranian Med 2009, pp. 225 - 231
[4] Karan S, Sudha B, Sharmeen S. Trend in sero prevalence of hepatits B virus infections among blood donors of coastal Karnetaka, India. J Infect Dev Ctries 2009, pp.376-379.
[5] Alter J, Kruson M. Hepatitis C virus infections. 1999, pp. 556-562.
[6] Jacobsn H , wirsama T . hepatitis A virus sero pre valence by age in world rigions , 1990 and 2005 . Vaccines. 2010, pp . 6653 - 6657.
[7] Eugene B, Chang. National Institute Of Health Consensus Development Conference Statement Management of Hepatitis C; 2002.
[8] Shagofta H , Nivin A , Rabea S. Hepatitis B and C Prevalence and Prevention Aware ness among health care workers in a tertiary care hospital . International Journal of Pathology. 2010, pp. 16-21.
[9] Kan A, and Loyd J. Hepatitis transmission and human immunodeficiency viruses through unsafe injections: model-based regional estimates. Bull World Health Organ 1999, pp. 801-807.
[10] Ali SWA, etal. Hepatitis B and C in Pakistan. Int J Infect Dis 2009, pp. 9-19.
[11] Chaudhry T, Khan J, Khan T. Prevalence of hepatitis B carriers and blood group frequencies in voluntary blood donors. J Ayub Med Coll Abbottabad 1996, pp. 29-32.
[12] Zhou etal. Hepatitis B and Hepatitis C Seroprevalence in Children Receiving Antiretroviral Therapy for Human Immunodeficiency Virus-1 Infection in China, 2005-2009 JAIDS Journal of Acquired Immune Deficiency Syndromes 2010, pp. 191-196
[13] Fayaz K and Khan A. Hepatitis B carriers among the volunteer blood donors at Quid-i-Azam Medical College Bhawalpur. Pro Med. J 2002, pp. 186-90.
[14] Ryas M, Hussain T, Bhatti FA. Epidem iology of hepatitis C virus infection in blood donors , northern Pakistan. J R Med Col 2001, pp. 56-59.
[15] Purrow B, Jacobson M. Slowing the progression of chronic hepatitis B, early antiviral therapy can help minimize complications. Postgrad Med 2003, pp. 65-76.
[16] Corell K and Saeed R. Variant Creutzfelt diseases in Australian blood donors, risk and the impacts of deferal strategies:Vox Sang 2001: pp.6- 11.
[17] Tozet S, Kramer L, and Colen C. Epidemiology of hepatitis virus infection in seven European Union countries: a critical analysis of the literature. HENCORE Group (Hepatitis C European Network for Cooperative Research). Eur J Gastroenterol Hepatol 2000, pp. 667-678.
[18] Al-Moslih M, Al-Hurabi M, prevalence of hepatitis C virus in patients with liver diseases in Republic of Yemen. Eastern Mediterranean Health Journal 2001, pp. 771-778.